Hello, everyone, and welcome to this investor call to discuss oveporexton Phase III data and commercial readiness. My name is Christopher O'Reilly, Head of Investor Relations at Takeda. Today's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results